Medicare overspent by 13.2 percent in 2017 and 20.6 percent in 2018 compared with Costco pharmacy member prices for the most commonly prescribed generic prescription drugs, according to a JAMA Network...
Launch prices for prescription drugs have doubled since 2005, according to researchers from Duke University’s Fuqua School of Business.
David Ridley, health economist and Fuqua strategy...
Thermo Fisher Scientific and UC Davis recently launched The Center of Excellence in Clinical Metabolomics to support the rapid scale-up of large cohort studies and clinical research.
The Center of...
Provention Bio recently announced that it received a complete response letter (CRL) from FDA in response to its biologics license application for its antibody, teplizumab, which aims to delay clinical...
Merck recently announced that FDA approved an expanded label for its anti-PD-1 therapy, Keytruda, as a monotherapy for patients with locally advanced cutaneous squamous cell carcinoma (cSCC).
The...
GSK and Alector recently entered into a strategic global collaboration to develop and commercialize two clinical-stage, potential first-in-class monoclonal antibodies for neurodegenerative...
AstraZeneca recently announced that its long-acting antibody, nirsevimab, demonstrated positive safety and tolerability profile in infants at high risk of respiratory syncytial virus (RSV) in a Phase...
Gilead recently submitted a new drug application to FDA seeking approval for its investigational, long-acting HIV-1 inhibitor, lenacapavir, for HIV treatment.
The submission is supported by data from...
Medicare drug spending reached $560 billion from 2016 through 2018, with pharmaceutical marketing accounting for nearly $324 billion in overall spending, according to a GAO study.
Of the 553...
Novo Nordisk recently announced that a 2.0-milligram dose of Ozempic elicited a “statistically significant and superior” reduction in HbA1C compared to Ozempic 1.0 milligram in...
Kite recently announced that its CAR T-cell therapy, Yescarta, improved event-free survival by 60 percent compared to the standard of care in a Phase 3 clinical trial.
After a median follow-up of two...
ViiV Healthcare and biopharmaceutical company Halozyme Therapeutics recently announced a global collaboration and license agreement to develop long-acting HIV treatment.
Under the agreement,...
Eli Lilly and Company recently announced that FDA granted breakthrough therapy designation for its investigational antibody therapy, donanemab, intended for Alzheimer’s disease.
This closely...
Regeneron recently announced that its COVID-19 antibody cocktail, REGEN-COV, reduced risk of death by 20 percent in patients hospitalized with COVID-19 who had not mounted their own immune...
Johnson & Johnson recently announced efficacy and safety data for its biologic therapy, Stelara (ustekinumab) in treating patients with Crohn’s disease and ulcerative colitis.
The...
FDA recently approved Janssen’s Rybrevant as the first targeted therapy for patients with subset of non-small cell lung cancer.
The agency approved the therapy based on a study of 81...
Medicago’s Coronavirus-Like Particle COVID-19 Vaccine Candidate (CoVLP) elicited significant humoral immune response across all age groups when administered in combination with GSK’s...
GSK and Sanofi’s COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses in a Phase 2 clinical trial, according to a recent press release.
The Phase 2 trial enrolled...
Merck recently announced that its anti-PD-1 therapy, Keytruda significantly helped patients with high-risk early-stage triple-negative breast cancer (TNBC)
The Phase 3 KEYNOTE-522 trial investigated...
A multisite test-negative design case-control CDC study recently found that the mRNA COVID-19 vaccines from Pfizer and Moderna are highly effective against symptomatic coronavirus.
The study analyzed...
